Effects of tibolone on health-related quality of life in menopausal women.
The present study assessed improvements in health-related quality of life (HRQOL) in menopausal women using tibolone. One hundred women who underwent surgical menopause for various benign gynecological conditions were advised to take tibolone (2.5 mg) daily. The Menopause Rating Scale (MRS II) was used to assess the change in HRQOL after 3 months and 12 months of treatment. Sixty-two women returned for follow-up after 3 months, while only 15 returned for after 12 months. Significant improvements in HRQOL were found after 3 months, and further improvements were obtained after 12 months, although at a slower rate. Among the three subscales of MRS, maximum improvement in the somatovegetative component and lesser improvements in the other two subscales were found. Tibolone is effective in improving the overall HRQOL of menopausal women. Somatovegetative symptoms show most improvement.